Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

May 2007

A Business Case for Quality

ByStephen A. Somers, PhD,Melanie Bella, MBA. Author reply by David A. Dorr, MD.

May 1st 2007

Current and Future Directions in Medi-Cal Chronic Disease Care Management: A View From the Top

ByL. Elizabeth Goldman, MD, MCR,Margaret Handley, PhD,Thomas G. Rundall, PhD,Dean Schillinger, MD

May 1st 2007

Willingness to Attend Group Visits for Hypertension Treatment

ByLumie Kawasaki, MD, MBA,Paul Muntner, PhD,Amanda D. Hyre, MPH,Kashley Hampton, BA,Karen B. DeSalvo, MD

May 1st 2007

The Response of Physician Groups to P4P Incentives

ByAteev Mehrotra, MD, MPH,Steven D. Pearson, MD, MSc,Kathryn L. Coltin, MPH,Ken P. Kleinman, PhD,Janice A. Singer, MPH,Barbra Rabson, MPH,Eric C. Schneider, MD, MSc

May 1st 2007

Physician-level P4P—DOA? Can Quality-based Payment Be Resuscitated?

ByLaurence F. McMahon Jr, MD, MPH,Timothy P. Hofer, MD,Rodney A. Hayward, MD

May 1st 2007

P4P: Rumors of Its Demise May Be Exaggerated

ByMeredith B. Rosenthal, PhD

May 1st 2007

Impact of Hospital Formularies on Fluoroquinolone Prescribing in Emergency Departments

BySherrie L. Aspinall, PharmD, MSc,Joshua P. Metlay, MD, PhD,Judith H. Maselli, MSPH,Ralph Gonzales, MD, MSPH

May 1st 2007

Trending on AJMC

Tec-Dara Demonstrates Superior 3-Year PFS vs Standard Therapy in Functional High-Risk Myeloma: Rahul Banerjee, MD

MRD-Guided CLL Treatment Duration: Personalization or Malpractice?

Global Hematology Trials Ensure Research Stays Applicable, Flexible, Patient-Centered

Blinatumomab Improves Outcomes, Toxicity in High-Risk Pediatric ALL: Martin Schrappe, MD, PhD

frontMIND Trial Shows PFS Benefit With Tafasitamab, Lenalidomide Combo in High-Risk DLBCL: Umberto Vitolo, MD